A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

410

Participants

Timeline

Start Date

May 6, 2020

Primary Completion Date

June 17, 2025

Study Completion Date

June 17, 2025

Conditions
Parkinson Disease
Interventions
DIETARY_SUPPLEMENT

Nicotinamide Riboside

Nicotinamide Riboside 500mg administered two times a day. Given as capsules. Duration of the trial; 52 weeks.

OTHER

Placebo

Placebo drug, administered two times a day. Given as capsules. Duration of the trial; 52 weeks.

Trial Locations (11)

Unknown

Bodø Hospital, Bodø

Arendal Hospital, Arendal

Haukeland University Hospital, Bergen

Vestre Viken Hospital, Drammen

Førde sykehus, Førde

Haugesund Hospital, Haugesund

Molde sjukehus, Molde

Akershus university hospital, Oslo

Oslo University Hospital, Oslo

University Hospital of North Norway, Tromsø

Østfold Hospital, Fredrikstad

All Listed Sponsors
collaborator

Oslo University Hospital

OTHER

collaborator

University Hospital, Akershus

OTHER

collaborator

Ostfold Hospital Trust

OTHER

collaborator

Førde Hospital Trust

OTHER

collaborator

Helse Fonna

OTHER

collaborator

Molde Hospital

OTHER

collaborator

Bodø sykehus

UNKNOWN

collaborator

Sorlandet Hospital HF

OTHER_GOV

collaborator

Drammen sykehus

OTHER

collaborator

University Hospital of Northern Norway, Tromsø, Norway

UNKNOWN

lead

Haukeland University Hospital

OTHER

NCT03568968 - A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease | Biotech Hunter | Biotech Hunter